ProEx C
This is a newly emerging technology being developed by Tripath
Imaging.
BD ProExC™ uses the fact that specific proteins are expressed
when DNA replication and control has been disrupted by HPV
oncoproteins E6 and E7 and cervical neoplasia has started to
develope. These proteins may be identified and quantified using
highly specific molecular biomarkers MCM2 and TOP2A.
BD ProExC™ has similar sensitivity to HPV tests but a higher
specficity for CIN2+ and thus can be used as a reflex test on
atypical BD SurePath™ LBC cytology results. Trials are currently
underway in UK.